For HER2-positive cancers, the guidelines advocate for dual-target therapies such as trastuzumab and pertuzumab, along with the introduction of pyrotinib in combination with trastuzumab as a novel ...

After a phase 3 study showed a promising pCR rate with HLX11, the pertuzumab biosimilar’s BLA has been accepted for review by the FDA.

FDA reviews biologics license application for HLX11, a biosimilar to pertuzumab, for HER2-positive breast cancer. The FDA accepted for review a biologics license application (BLA) seeking the approval ...

The addition of trastuzumab and pertuzumab to chemotherapy was associated with increased toxicity in patients with HER2-positive gastric cancers enrolled in the INNOVATION trial. In patients with HER2 ...

These participants were randomly assigned to treatment with either a combination of the HER2 inhibitors trastuzumab (Herceptin) and pertuzumab (Perjeta) (TP) every three weeks or a standard EGFR ...

We are working with Guy’s and St. Thomas’ NHS Foundation Trust to produce national standardised SACT regimen-specific consent forms. We want to support clinicians in ensuring all patients are fully ...

In this trial, patients with node-positive or high-risk node-negative (HR negative and tumor size >2cm) HER2-positive breast cancer were randomly assigned to anthracycline chemotherapy followed by ...

Since there are reports of patients co-manifesting the two hypersensitivities, a common mechanism may underlie both the TCR and IgE nickel binding. Focusing on Trastuzumab and Pertuzumab IgE variants ...